Cholangiocarcinoma

Updated FOENIX-CCA2 trial results were found to be consistent with the primary analysis, indicating durable efficacy and continued tolerability of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements. Read More ›

Phase 3 TOPAZ-1 clinical trial established durvalumab plus gemcitabine/cisplatin as a viable first-line standard-of-care treatment regimen for advanced biliary tract cancer. Read More ›

The Cholangiocarcinoma Foundation hosts a patient registry, the International Cholangiocarcinoma Patient Registry (ICPR), that is a global database comprising patient medical histories and treatments for cholangiocarcinoma (CCA). Read More ›

A single-institution experience in treating patients with metastatic iCCA with local liver-directed radiation therapy (RT) was presented by Rituraj Upadhyay, MD, at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

Based on their anatomic site of origin, cholangiocarcinomas (CCAs) are classified as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Read More ›

At the 2022 Cholangiocarcinoma Foundation (CCF) Annual Conference on Melinda Bachini, Director of Advocacy of CCF, provided an update on the foundation’s advocacy and patient support initiatives. Read More ›

The International Cholangiocarcinoma Research Network (ICRN) is a program initiated by the Cholangiocarcinoma Foundation (CCF). The core mission of this network of international experts is “to rapidly translate scientific discoveries into practice for cholangiocarcinoma patients through a collaborative, highly translational international research network. Read More ›

Mitesh J. Borad, MD, Mayo Clinic College of Medicine and Science, Phoenix, AZ, delivered an expert Keynote Perspective at the Third Annual CCA Summit, highlighting genomic profiling as the standard of care in the management of patients with intrahepatic cholangio­carci­noma (CCA), with liquid biopsy becoming the tool of choice for geno­mic profiling in biliary tract cancers. Read More ›

Cholangiocarcinoma (CCA) involves genetic heterogeneity, highlighting the need to identify new inherited variants, as discussed at the 3rd Annual CCA Summit in Session II, “Molecular Epidemiology of CCA.” Read More ›

I believe that the most powerful and positive force in medicine is that of a self-advocating patient. At the Cholangiocarcinoma Foundation, we strive to connect, educate, and empower patients with cholangiocarcinoma (CCA) to partner with their care team in navigating the course of their treatment. However, we understand that the treatment options are extremely limited for many patients with CCA. Read More ›